ClinicalTrials.gg
CompletedNCT00355615Updated Aug 31, 2011Results posted

PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin

A Phase 3 interventional study of Rosuvastatin and Placebo in Familial Hypercholesterolemia, sponsored by AstraZeneca. Completed at 20 sites in 5 countries. Open to participants aged 10 Years to 17 Years. Per ClinicalTrials.gov, last updated 2011-08-31.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
173
Allocation
Randomized
Ages
10 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands — 5 open to participants now, 7 under way, 4 of them phase 3. Hyperlipoproteinemia Type II · Netherlands.

Enrollment
14th of 33
173 · median 153
Started
2006
with 2 others
Phase 3
14 of 35
3 open now
Registered
7th of 35
by date
Lead sponsor
2 of 35
AstraZeneca

Among the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, this one is the 14th largest by enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2006, is one of 14 in phase 3, and was the 7th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

5 of the 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 10 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Hyperlipoproteinemia Type II with a site in Netherlands, or all of them as a file.
02

Study summary

The primary objective of this study is to determine the efficacy of once-daily rosuvastatin in reducing LDL-C in children and adolescents aged 10-17 years with HeFH from baseline (Day 0) to the end of the 12-week double-blind treatment period.

03

Conditions studied

  • Familial Hypercholesterolemia

Keywords

  • Heterozygous Familial Hypercholesterolemia
04

Who can participate

Ages eligible
10 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female (at least 1 year post-menarche) children and adolescents (aged 10 -17 years) with heterozygous familial hypercholesterolemia (HeFH)

Exclusion criteria

Exclusion Criteria:

  • Certain medical conditions and lab test results
  • History of a reaction to rosuvastatin or other statin drugs
  • Use of specified disallowed medications
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
173 participants (actual)

Study arms

  • Active comparator
    rosuva 5

    rosuvastatin 5 mg

    Drug: Rosuvastatin

  • Active comparator
    rosuva 10

    rosuvastatin 10 mg

    Drug: Rosuvastatin

  • Active comparator
    rosuva 20

    rosuvastatin 20 mg

    Drug: Rosuvastatin

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo

  • Other
    rosuva ol

    rosuvastatin open label

    Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase

    Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value \* 100

    Time frame: 12 weeks

Secondary outcomes

  1. Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)

    Percent change from baseline in LDL-C after six week of treatment

    Time frame: 6 weeks

  2. Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment

    Percent of patients achieving LDL-C \< 110 mg/dL out of the total patients in each treatment group

    Time frame: 12 weeks

  3. Percent Change in HDL-C

    Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

  4. Percent Change in Non-HDL-C at 12 Weeks

    Percent change in non-HDL-C at 12 weeks

    Time frame: After 12 weeks of treatment

  5. Percent Change in Triglycerides (TG)

    Percent change in tryglycerides (TG) after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

  6. Percent Change in Total Cholesterol (TC)

    Percent change from baseline in total cholesteral after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

  7. Percent Change in Apolipoprotein A-1 (ApoA-1)

    Percent change in ApoA-1 after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

  8. Percent Change in Apolipoprotein B (ApoB)

    Percent change in ApoB after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

  9. Percent Change in ApoB/ApoA-1

    Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

  10. Percent Change in LDL-C/HDL-C

    Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment

    Time frame: After 12 week of treatment

  11. Percent Change in TC/HDL-C

    Percent change in the ratio of TC/HDL-C after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

  12. Percent Change in Non-HDL-C/HDL-C

    Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment

    Time frame: After 12 weeks of treatment

07

Results

Posted Jul 20, 2009

Participant flow

One-hundred male and female (Tanner stages II to V, at least 1 year post-menarche) children and adolescents (aged 10 to 17 years with Heterozygous familial hypercholesterolemia were randomized into the study, from 20 sites located in The United States (3 sites), The Netherlands (7 sites), Norway (1 site), Spain (3 sites), and Canada (6 sites).

Randomized Double Blind Period
Participant flow — Randomized Double Blind Period
MilestoneRosuva 5Rosuva 10Rosuva 20PlaceboRosuva ol
Started424445460
Completed414444450
Not completed10110
Withdrew: Adverse event10000
Withdrew: Protocol violation00110
40-week Rosuvastatin Open Label Period
Participant flow — 40-week Rosuvastatin Open Label Period
MilestoneRosuva 5Rosuva 10Rosuva 20PlaceboRosuva ol
Started0000173
Completed0000164
Not completed00009
Withdrew: Adverse event00004
Withdrew: Protocol violation00001
Withdrew: Withdrawal by subject00003
Withdrew: Investigational site closed00001

Outcome measures

PrimaryPercent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase

Percent change in low-density lipoprotein cholesterol (LDL-C) = (final value - Baseline value)/Baseline value \* 100

Time frame:
12 weeks
Reported as:
Mean · percentage
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase
percentageRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in Low-density Lipoprotein Cholesterol (LDL-C) From Baseline (Day 0) to the End of the 12-week Double-blind Treatment Phase-38.5 ± 11.38-44.4 ± 12.15-50.2 ± 13.3-0.5 ± 13.18
SecondaryPercent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)

Percent change from baseline in LDL-C after six week of treatment

Time frame:
6 weeks
Reported as:
Mean · percentage
Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)
percentageRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in LDL-C and Other Lipid Parameters From Baseline to Week 6, and at End of Double-blind Dose Treatment Phase (Week 12)-40.3 ± 12.22-45.2 ± 11.15-50.0 ± 11.42-0.6 ± 13.63
SecondaryPercent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment

Percent of patients achieving LDL-C \< 110 mg/dL out of the total patients in each treatment group

Time frame:
12 weeks
Reported as:
Number · Percent of Participants
Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment
Percent of ParticipantsRosuva 5Rosuva 10Rosuva 20Placebo
Percent Control Rate Based on Achievement of LDL-C Target of <110 mg/dL During Double-blind Dose Treatment11.940.940.90.0
SecondaryPercent Change in HDL-C

Percent change in high-density lipoprotein cholesterol (HDL-C) after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · percent change
Percent Change in HDL-C
percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in HDL-C4.5 ± 15.5310.1 ± 14.198.9 ± 14.117.6 ± 17.89
SecondaryPercent Change in Non-HDL-C at 12 Weeks

Percent change in non-HDL-C at 12 weeks

Time frame:
After 12 weeks of treatment
Reported as:
Mean · percent change
Percent Change in Non-HDL-C at 12 Weeks
percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in Non-HDL-C at 12 Weeks-36.3 ± 9.98-42.8 ± 11.50-47.7 ± 13.50-0.8 ± 11.89
SecondaryPercent Change in Triglycerides (TG)

Percent change in tryglycerides (TG) after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · percent change
Percent Change in Triglycerides (TG)
percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in Triglycerides (TG)2.6 ± 49.07-14.2 ± 29.66-7.9 ± 55.883.4 ± 48.27
SecondaryPercent Change in Total Cholesterol (TC)

Percent change from baseline in total cholesteral after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · percent change
Percent Change in Total Cholesterol (TC)
percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in Total Cholesterol (TC)-30.0 ± 9.63-34.1 ± 9.5-38.9 ± 12.080.2 ± 10.53
SecondaryPercent Change in Apolipoprotein A-1 (ApoA-1)

Percent change in ApoA-1 after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · mean percent change
Percent Change in Apolipoprotein A-1 (ApoA-1)
mean percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in Apolipoprotein A-1 (ApoA-1)2.3 ± 9.694.3 ± 9.853.9 ± 10.683.6 ± 15.59
SecondaryPercent Change in Apolipoprotein B (ApoB)

Percent change in ApoB after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · mean percent change
Percent Change in Apolipoprotein B (ApoB)
mean percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in Apolipoprotein B (ApoB)-32.1 ± 9.13-37.8 ± 11.75-40.7 ± 13.91-1.5 ± 14.67
SecondaryPercent Change in ApoB/ApoA-1

Percent change in the ratio of ApoB/ApoA-1 after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · mean percent change
Percent Change in ApoB/ApoA-1
mean percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in ApoB/ApoA-1-33.1 ± 9.99-40.0 ± 12.06-42.8 ± 12.23-3.4 ± 16.70
SecondaryPercent Change in LDL-C/HDL-C

Percent change in the ratio of LDL-C/HDL-C after 12 weeks of treatment

Time frame:
After 12 week of treatment
Reported as:
Mean · mean percent change
Percent Change in LDL-C/HDL-C
mean percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in LDL-C/HDL-C-40.4 ± 11.36-48.6 ± 13.26-53.6 ± 12.85-5.5 ± 17.98
SecondaryPercent Change in TC/HDL-C

Percent change in the ratio of TC/HDL-C after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · mean percent change
Percent Change in TC/HDL-C
mean percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in TC/HDL-C-32.1 ± 10.72-39.3 ± 11.55-43.2 ± 11.76-5.2 ± 15.03
SecondaryPercent Change in Non-HDL-C/HDL-C

Percent change in the ratio of non-HDL-C/HDL-C after 12 weeks of treatment

Time frame:
After 12 weeks of treatment
Reported as:
Mean · mean percent change
Percent Change in Non-HDL-C/HDL-C
mean percent changeRosuva 5Rosuva 10Rosuva 20Placebo
Percent Change in Non-HDL-C/HDL-C-37.9 ± 12.12-47.1 ± 13.12-51.2 ± 13.18-5.8 ± 17.63

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rosuva 5———
Rosuva 10———
Rosuva 20———
Placebo———
Rosuva ol———
Most frequent serious events
Most frequent serious events
EventRosuva 5Rosuva 10Rosuva 20PlaceboRosuva ol
Vision BlurredEye disorders0/420/440/441/460/173
AppendicitisInfections and infestations0/420/440/440/461/173
Rash VesicularSkin and subcutaneous tissue disorders0/420/440/440/461/173
Most frequent other events
Most frequent other events
EventRosuva 5Rosuva 10Rosuva 20PlaceboRosuva ol
NasopharyngitisInfections and infestations3/427/447/445/4636/173
HeadacheNervous system disorders6/427/449/449/4629/173
InfluenzaInfections and infestations2/422/440/444/4614/173
TonsillitisGastrointestinal disorders0/420/443/441/462/173
NauseaGastrointestinal disorders2/420/442/442/4610/173
FatigueGeneral disorders1/421/441/440/469/173

Baseline characteristics

Age Continuous
Age Continuous(years)Rosuva 5Rosuva 10Rosuva 20PlaceboTotal
Mean14.1 (10 to 17)14.5 (11 to 17)14.2 (11 to 17)14.3 (10 to 17)14.3 (10 to 17)
Sex: Female, Male
Sex: Female, Male(Participants)Rosuva 5Rosuva 10Rosuva 20PlaceboTotal
Female2625222497
Male1619232280
Baseline low-density lipoprotein cholesterol (LDL-C)
Baseline low-density lipoprotein cholesterol (LDL-C)(mg/dL)Rosuva 5Rosuva 10Rosuva 20PlaceboTotal
Mean237.70 ± 55.06229.10 ± 44.70237.40 ± 47.80229.00 ± 43.13233.3 ± 10.0
08

Study locations

20 sites
  • Research Site
    Los Angeles, California, United States
  • Research Site
    Hyde Park, New York, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Wexford, Pennsylvania, United States
  • Research Site
    Hamilton, Ontario, Canada
  • Research Site
    Toronto, Ontario, Canada
  • Research Site
    Chicoutimi, Quebec, Canada
  • Research Site
    Laval, Quebec, Canada
  • Research Site
    Sherbrook, Quebec, Canada
  • Research SIte
    Amsterdam, Netherlands
  • Research Site
    Eindhoven, Netherlands
  • Research Site
    Groningen, Netherlands
  • Research Site
    Hoorn, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Utrecht, Netherlands
  • Research SIte
    Waalwijk, Netherlands
  • Research Site
    Oslo, Norway
  • Research Site
    Cordoba, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Reus, Spain
09

References and documents

Publications

  • Avis HJ, Hutten BA, Gagne C, Langslet G, McCrindle BW, Wiegman A, Hsia J, Kastelein JJ, Stein EA. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010 Mar 16;55(11):1121-6. doi: 10.1016/j.jacc.2009.10.042. PubMed 20223367 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2006
First posted
Jul 24, 2006
Start
Jul 2006
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Jul 20, 2009
Last update
Aug 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00355615
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 24, 2006
Start date
Jul 2006
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Jul 20, 2009
Last update
Aug 31, 2011

Study contacts

Crestor Medical Science Director, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion